Adrenergic vasoconstriction augments tissue O2 extraction during reductions in O2 delivery.
When systemic O2 delivery is reduced, increases in systemic O2 extraction are facilitated by sympathetically mediated increases in vascular resistance that limit blood flow to regions with low metabolic demand. Local metabolic vasodilation competes with this vasoconstriction, thereby effecting a balance between tissue O2 supply and demand. This study examined the role of sympathetically mediated vasoconstriction on the critical level of O2 extraction in hindlimb and whole body during progressive reductions in O2 delivery. In anesthetized dogs, the left hindlimb was vascularly isolated and its O2 delivery was decreased in stages by reducing the speed of an occlusive pump. In a normovolemic group (n = 6), blood volume was maintained to minimize sympathetic tone while flow to the hindlimb was reduced. In a hypovolemic group (n = 6), blood volume was removed in stages to augment sympathetic tone progressively while flow to the limb was reduced simultaneously. A phenoxybenzamine group (n = 6) was identical to the hypovolemic group, except that alpha-adrenergic effects were inhibited with phenoxybenzamine (3 mg/kg). The systemic critical O2 extraction ratio in the phenoxybenzamine group (0.60 +/- 0.06) was less than for the hypovolemic group (0.71 +/- 0.04; P = 0.004). In the hindlimb, critical O2 extractions were significantly less in the normovolemic (0.46 +/- 0.17) and phenoxybenzamine (0.49 +/- 0.10) groups compared with the hypovolemic group (0.72 +/- 0.10; P < or = 0.008).(ABSTRACT TRUNCATED AT 250 WORDS)
Maginniss
L A
LA
Department of Medicine, University of Chicago, Illinois 60637.
Connolly
H
H
Samsel
R W
RW
Schumacker
P T
PT
D000136:Acid-Base Equilibrium / Q000502:physiology; D000818:Animals; D001784:Blood Gas Analysis; D004285:Dogs; D006439:Hemodynamics / Q000502:physiology; D006614:Hindlimb / Q000098:blood supply / Q000502:physiology; D000860:Hypoxia / Q000503:physiopathology*; D066298:In Vitro Techniques; D008833:Microcirculation / Q000502:physiology; D010101:Oxygen Consumption / Q000502:physiology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology; D012039:Regional Blood Flow / Q000502:physiology; D012769:Shock / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000502:physiology*; D014661:Vasoconstriction / Q000502:physiology*
D011942:Receptors, Adrenergic, alpha; D010643:Phenoxybenzamine